236 related articles for article (PubMed ID: 26527069)
1. Drugging Undruggable Molecular Cancer Targets.
Lazo JS; Sharlow ER
Annu Rev Pharmacol Toxicol; 2016; 56():23-40. PubMed ID: 26527069
[TBL] [Abstract][Full Text] [Related]
2. Drugging the 'undruggable' cancer targets.
Dang CV; Reddy EP; Shokat KM; Soucek L
Nat Rev Cancer; 2017 Aug; 17(8):502-508. PubMed ID: 28643779
[TBL] [Abstract][Full Text] [Related]
3. Drugging RAS: Know the enemy.
Papke B; Der CJ
Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
[TBL] [Abstract][Full Text] [Related]
4. Targeting oncogenic drivers.
Zhao Y; Adjei AA
Prog Tumor Res; 2014; 41():1-14. PubMed ID: 24727983
[TBL] [Abstract][Full Text] [Related]
5. Drugging the undruggable: transcription therapy for cancer.
Yan C; Higgins PJ
Biochim Biophys Acta; 2013 Jan; 1835(1):76-85. PubMed ID: 23147197
[TBL] [Abstract][Full Text] [Related]
6. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.
Würth R; Thellung S; Bajetto A; Mazzanti M; Florio T; Barbieri F
Drug Discov Today; 2016 Jan; 21(1):190-199. PubMed ID: 26456577
[TBL] [Abstract][Full Text] [Related]
7. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.
Cai SF; Chen CW; Armstrong SA
Mol Cell; 2015 Nov; 60(4):561-70. PubMed ID: 26590715
[TBL] [Abstract][Full Text] [Related]
8. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Seo SY
Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
[TBL] [Abstract][Full Text] [Related]
9. Precision cancer medicine: where to target?
Yu Q; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
[No Abstract] [Full Text] [Related]
10. Network pharmacology for cancer drug discovery: are we there yet?
Azmi AS
Future Med Chem; 2012 May; 4(8):939-41. PubMed ID: 22650234
[No Abstract] [Full Text] [Related]
11. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
13. Q&A: Ashok Venkitaraman on "undruggable" targets. Interview by Eric Bender.
Venkitaraman A
Cancer Discov; 2013 Jun; 3(6):597. PubMed ID: 23749513
[No Abstract] [Full Text] [Related]
14. The emerging role of CXC chemokines and their receptors in cancer.
Vinader V; Afarinkia K
Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets and targeted therapeutics in endometrial cancer.
Weigelt B; Banerjee S
Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
[TBL] [Abstract][Full Text] [Related]
16. DNA repair: a reinvigorated therapeutic target.
Bates SE
Clin Cancer Res; 2010 Sep; 16(18):4510. PubMed ID: 20823139
[No Abstract] [Full Text] [Related]
17. The impact of molecular targets in cancer drug development: major hurdles and future strategies.
Hebar A; Valent P; Selzer E
Expert Rev Clin Pharmacol; 2013 Jan; 6(1):23-34. PubMed ID: 23272790
[TBL] [Abstract][Full Text] [Related]
18. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.
Verdine GL; Walensky LD
Clin Cancer Res; 2007 Dec; 13(24):7264-70. PubMed ID: 18094406
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in oncology come of age.
Klein A
Clin Ther; 2013 Sep; 35(9):1256-7. PubMed ID: 24054702
[No Abstract] [Full Text] [Related]
20. Taking Aim at the Undruggable.
Coleman N; Rodon J
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-8. PubMed ID: 33989024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
